Published in World J Hepatol on November 18, 2015
Clinicopathological role of miR-30a-5p in hepatocellular carcinoma tissues and prediction of its function with bioinformatics analysis. Onco Targets Ther (2016) 0.78
Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract (2016) 0.77
A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Mol Pharmacol (2015) 0.77
Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma. Hepatobiliary Surg Nutr (2016) 0.76
Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma. Oncotarget (2017) 0.75
The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol (2017) 0.75
Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ Sci B (2017) 0.75
Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012. World J Gastroenterol (2016) 0.75
Evaluation of Novel (64)Cu-Labeled Theranostic Gadolinium-Based Nanoprobes in HepG2 Tumor-Bearing Nude Mice. Nanoscale Res Lett (2017) 0.75
Role of C-X-C chemokine ligand 12/C-X-C chemokine receptor 4 in the progression of hepatocellular carcinoma. Oncol Lett (2017) 0.75
Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget (2017) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet (1963) 10.22
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Inflammation, a key event in cancer development. Mol Cancer Res (2006) 5.03
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Molecular viral oncology of hepatocellular carcinoma. Oncogene (2003) 3.58
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl (2014) 3.11
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology (2014) 3.05
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol (2003) 2.87
New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology (2013) 2.76
Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72
Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther (2014) 2.66
The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl (2004) 2.65
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int (2014) 2.26
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer (2012) 2.10
Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant (2008) 2.06
Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl (2008) 2.04
Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut (2011) 1.98
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol (2008) 1.98
Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 1.97
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol (2013) 1.87
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation (2009) 1.69
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol (2006) 1.56
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci (2012) 1.45
Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg (2011) 1.44
LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology (2014) 1.31
Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl (2007) 1.27
Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant (2008) 1.27
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 1.25
An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther (2012) 1.18
Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol (2014) 1.18
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl (2012) 1.18
Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther (2012) 1.17
Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue. J Hepatol (2013) 1.15
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One (2014) 1.15
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15
Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant (2012) 1.15
Molecular pathogenesis of hepatocellular carcinoma. J Surg Res (2006) 1.15
Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol (2012) 1.12
The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. J Gastrointest Surg (2015) 1.09
Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl (2006) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc (2005) 1.02
Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer (2014) 1.00
Liver transplantation for hepatocellular carcinoma in Asia. Oncologist (2007) 0.99
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc (2014) 0.96
Clinical evaluation of liver disease. Baillieres Clin Gastroenterol (1995) 0.95
Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry. Clin Transpl (2012) 0.94
New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer (2012) 0.92
HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int (2013) 0.92
Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl (2014) 0.91
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl (2014) 0.91
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One (2014) 0.91
Liver transplantation for hepatocellular carcinoma: role of biopsy. Liver Transpl (2007) 0.91
Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system. Liver Transpl (2011) 0.91
Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis (2012) 0.91
Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. Liver Transpl (2014) 0.90
Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) (2010) 0.90
Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther (2014) 0.90
Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol (2013) 0.89
Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol (2004) 0.88
Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res (2012) 0.88
Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl (2008) 0.87
Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl (2007) 0.85
Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford) (2013) 0.85
Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr (2013) 0.85
Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol (2013) 0.85
Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. J Hepatol (2011) 0.84
Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria. PLoS One (2014) 0.84
Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev (2014) 0.84
Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer. World J Surg Oncol (2014) 0.83
Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score. Clin Gastroenterol Hepatol (2013) 0.83
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2013) 0.82
Usefulness of the Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma. Liver Transpl (2010) 0.81
Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci (2009) 0.81
Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials? Liver Transpl (2007) 0.81
Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology (2014) 0.81